The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 and BI 754111 in patients (pts) with advanced solid tumors.
 
Anthony W. Tolcher
Employment - Next Oncology; START
Leadership - Symphogen
Consulting or Advisory Role - AbbVie (Inst); AbGenomics International (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aro Biotherapeutics (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Axiom Biotechnologies (Inst); Bayer (Inst); BioInvent (Inst); Boston Biomedical (Inst); Cello Health (Inst); EMD Serono (Inst); Forbius (Inst); Genentech/Roche (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); Immunome (Inst); Immunome (Inst); Immunome (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nuvalent, Inc. (Inst); OSI Pharmaceuticals (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pierre Fabre (Inst); Ridgeway Therapeutics (Inst); Scientex (Inst); Seagen (Inst); Sesen Bio (Inst); Seven and Eight Biopharmaceuticals (Inst); Symphogen (Inst); Syneos Health (Inst)
Research Funding - AbbVie (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Arrys Therapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Boehringer Ingelheim (Inst); CStone Pharmaceuticals (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Naturewise (Inst); NextCure (Inst); Nitto BioPharma (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Samumed (Inst); Seagen (Inst); Seven and Eight Biopharmaceuticals (Inst); Sound Biologics (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
 
Navid Hafez
No Relationships to Disclose
 
Noboru Yamamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Sysmex
Consulting or Advisory Role - ASLAN Pharmaceuticals; Boehringer Ingelheim; Eisai; Otsuka; PRA health science; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); IQVIA (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Jaehong Park
Employment - Boehringer Ingelheim
 
Rolf Grempler
Employment - Boehringer Ingelheim
Stock and Other Ownership Interests - Roche; Roche (I)
Patents, Royalties, Other Intellectual Property - Boehringer Ingelheim
 
Anthony G. Lucarelli
Employment - Boehringer Ingelheim
Stock and Other Ownership Interests - Taro
 
Mehdi Lahmar
Employment - Boehringer Ingelheim
Stock and Other Ownership Interests - Valneva
Patents, Royalties, Other Intellectual Property - Gamamabs Pharma; Valneva
 
Bushi Wang
Employment - Boehringer Ingelheim; Boehringer Ingelheim
 
Mrinal M. Gounder
Honoraria - Bayer; Flatiron Health; Medscape; PER
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; Springworks Therapeutics
Speakers' Bureau - Amgen
Patents, Royalties, Other Intellectual Property - UpToDate
Travel, Accommodations, Expenses - Epizyme
Other Relationship - Desmoid Tumor Research Foundation
(OPTIONAL) Uncompensated Relationships - Foundation Medicine